Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.

PubWeight™: 7.61‹?› | Rank: Top 0.1%

🔗 View Article (PMID 17321312)

Published in Lancet on February 24, 2007

Authors

Joost Daemen1, Peter Wenaweser, Keiichi Tsuchida, Linda Abrecht, Sophia Vaina, Cyrill Morger, Neville Kukreja, Peter Jüni, Georgios Sianos, Gerrit Hellige, Ron T van Domburg, Otto M Hess, Eric Boersma, Bernhard Meier, Stephan Windecker, Patrick W Serruys

Author Affiliations

1: Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Dr Molewaterplein 40,3015 GD Rotterdam, Netherlands.

Associated clinical trials:

Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents (ORAR III) | NCT00552669

RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent) (RIBS IV) | NCT01239940

RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent) (RIBS V) | NCT01239953

Six-month Coverage and Vessel Wall Response of the Zotarolimus Drug-eluting Stent Implanted in AMI Assessed by Optical Coherence Tomography (OCTAMI) | NCT00704561

Percutaneous Coronary Intervention With the Angiolite Drug-eluting Stent: an Optical Cohenrece Tomography Study | NCT02776267

Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation | NCT02176265

Drug-Coated Balloon Coronary Angioplasty Versus Stenting for Treatment of Disease Adjacent to a Chronic Total Occlusion. (Co-CTO) | NCT04881812

Intra-patient Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT (Optical Coherence Tomography) Follow up | NCT02785237

BES, EES, and ZES-R in Real World Practice (CHOICE) | NCT01397175

Articles citing this

(truncated to the top 100)

The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol (2011) 3.71

Coronary revascularization trends in the United States, 2001-2008. JAMA (2011) 2.81

Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents. JAMA (2008) 2.47

Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ (2008) 2.09

The long-term effect of coronary stenting on epicardial and microvascular endothelial function. Circ Cardiovasc Interv (2012) 2.03

Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci Transl Med (2011) 1.84

Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation (2008) 1.68

Metabolic syndrome and coronary artery disease in Ossabaw compared with Yucatan swine. Comp Med (2010) 1.61

A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. J Clin Invest (2014) 1.52

Trends in coronary revascularization in the United States from 2001 to 2009: recent declines in percutaneous coronary intervention volumes. Circ Cardiovasc Qual Outcomes (2011) 1.51

Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv (2008) 1.49

Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ (2013) 1.32

Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J (2015) 1.29

Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol (2008) 1.18

Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience. JACC Cardiovasc Interv (2011) 1.16

Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries. Circulation (2008) 1.10

Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation. Circ Res (2009) 1.01

Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy. Eur Heart J (2010) 1.01

Ultra-thin strut cobalt chromium bare metal stent usage in a complex real-world setting. (SOLSTICE registry). Neth Heart J (2015) 0.99

Very late thrombosis of a drug-eluting stent after discontinuation of dual antiplatelet therapy in a patient treated with both drug-eluting and bare-metal stents. Korean Circ J (2009) 0.99

Thrombus causes fluctuations in arterial drug delivery from intravascular stents. J Control Release (2008) 0.95

Current characteristics and management of ST elevation and non-ST elevation myocardial infarction in the Tokyo metropolitan area: from the Tokyo CCU network registered cohort. Heart Vessels (2016) 0.95

Second- and third-generation drug-eluting coronary stents: progress and safety. Herz (2011) 0.93

Stent evaluation with optical coherence tomography. Yonsei Med J (2013) 0.92

Late stent thrombosis, endothelialisation and drug-eluting stents. Neth Heart J (2009) 0.91

Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord (2010) 0.90

Antioxidant enzyme gene transfer for ischemic diseases. Adv Drug Deliv Rev (2009) 0.90

Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy. Heart (2007) 0.90

Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial. Heart Vessels (2012) 0.90

Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clin Res Cardiol (2010) 0.90

Changes in the Practice of Coronary Revascularization between 2006 and 2010 in the Republic of Korea. Yonsei Med J (2015) 0.89

Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation. J Am Coll Cardiol (2013) 0.89

First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart (2014) 0.88

Restenosis after PCI. Part 2: prevention and therapy. Nat Rev Cardiol (2011) 0.88

Nanomedicine for the reduction of the thrombogenicity of stent coatings. Int J Nanomedicine (2010) 0.88

Stent thrombosis: incidence, predictors and new technologies. Thrombosis (2012) 0.87

Short- and long-term benefits of drug-eluting stents compared to bare metal stents even in treatment for large coronary arteries. Heart Vessels (2015) 0.87

Surface modification of a polyhedral oligomeric silsesquioxane poly(carbonate-urea) urethane (POSS-PCU) nanocomposite polymer as a stent coating for enhanced capture of endothelial progenitor cells. Biointerphases (2013) 0.86

Complete versus incomplete revascularization for treatment of multivessel coronary artery disease in the drug-eluting stent era. Heart Vessels (2011) 0.86

Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. J Am Coll Cardiol (2012) 0.86

Clinical outcomes of different first- and second-generation drug-eluting stents in routine clinical practice: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol (2013) 0.85

The effect of cilostazol on stent thrombosis after drug-eluting stent implantation. Korean Circ J (2010) 0.85

Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.84

Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy. Heart (2007) 0.84

Advantages and disadvantages of biodegradable platforms in drug eluting stents. World J Cardiol (2011) 0.84

Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv (2015) 0.83

Major determinants for the uncovered stent struts on optical coherence tomography after drug-eluting stent implantation. Int J Cardiovasc Imaging (2011) 0.83

The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I) : the one-year clinical follow-up. Clin Res Cardiol (2007) 0.83

Cannabinoid receptor CB2 protects against balloon-induced neointima formation. Am J Physiol Heart Circ Physiol (2012) 0.83

Coronary stent healing, endothelialisation and the role of co-medication. Neth Heart J (2007) 0.83

Second generation drug-eluting stents: a review of the everolimus-eluting platform. Clin Med Insights Cardiol (2013) 0.83

Optimal revascularization for complex coronary artery disease. Nat Rev Cardiol (2013) 0.83

Comparison of optical coherence tomographic assessment between first- and second-generation drug-eluting stents. Yonsei Med J (2012) 0.83

Long-term (≥2 years) follow-up optical coherence tomographic study after sirolimus- and paclitaxel-eluting stent implantation: comparison to 9-month follow-up results. Int J Cardiovasc Imaging (2010) 0.82

Are drug-eluting stents safe in the long term? CMAJ (2008) 0.82

Clinical outcomes in low risk coronary artery disease patients treated with different limus-based drug-eluting stents--a nationwide retrospective cohort study using insurance claims database. PLoS One (2015) 0.82

Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History). Int J Cardiovasc Imaging (2011) 0.82

A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients. Indian Heart J (2012) 0.81

Percutaneous coronary intervention for unprotected left main disease in very high risk patients: safety of drug-eluting stents. Heart Vessels (2010) 0.81

Pathological perspective of drug-eluting stent thrombosis. Thrombosis (2012) 0.81

Comparison of Two Different Strategies of Intravascular Ultrasound Guidance during Percutaneous Coronary Intervention; Routine versus Selective. Korean Circ J (2013) 0.81

Association of localized hypersensitivity and in-stent neoatherosclerosis with the very late drug-eluting stent thrombosis. PLoS One (2014) 0.81

Clinical outcomes of second- versus first-generation drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Arch Med Sci (2014) 0.81

Paclitaxel-eluting versus sirolimus-eluting stents in diabetes mellitus: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. Circ Cardiovasc Interv (2010) 0.81

Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy. Thromb J (2008) 0.81

Multifaceted prospects of nanocomposites for cardiovascular grafts and stents. Int J Nanomedicine (2015) 0.81

Enhanced endothelialization on surface modified poly(L-lactic acid) substrates. Tissue Eng Part A (2010) 0.81

Drug-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: a mortality analysis from the EUROTRANSFER Registry. Clin Res Cardiol (2010) 0.80

Comparison of outcome in 1809 patients treated with drug-eluting stents or bare-metal stents in a real-world setting. Vasc Health Risk Manag (2011) 0.80

Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. J Am Heart Assoc (2016) 0.80

An anti-CD34 antibody-functionalized clinical-grade POSS-PCU nanocomposite polymer for cardiovascular stent coating applications: a preliminary assessment of endothelial progenitor cell capture and hemocompatibility. PLoS One (2013) 0.80

Short-term consequences of angiographically-confirmed coronary stent thrombosis. PLoS One (2013) 0.80

Targeting PI3Kγ activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 response. J Exp Med (2014) 0.80

Everolimus-eluting stents in interventional cardiology. Vasc Health Risk Manag (2012) 0.80

The invasive assessment of coronary atherosclerosis and stents using optical coherence tomography: a clinical update. Heart Asia (2013) 0.80

Efficacy and safety of biodegradable polymer biolimus-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. PLoS One (2013) 0.80

Nitinol-based nanotubular coatings for the modulation of human vascular cell function. Nano Lett (2014) 0.79

The relationship between re-endothelialization and endothelial function after DES implantation: comparison between paclitaxcel eluting stent and zotarolims eluting stent. Catheter Cardiovasc Interv (2014) 0.79

A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease. Biologics (2013) 0.79

Everolimus-eluting stents improve vascular response in a diabetic animal model. Circ Cardiovasc Interv (2014) 0.79

The risk of definitive stent thrombosis is increased after "off-label" stent implantation irrespective of drug-eluting stent or bare-metal stent use. Clin Res Cardiol (2009) 0.79

Comparison of drug-eluting stents in acute myocardial infarction patients with chronic kidney disease. Korean J Intern Med (2012) 0.79

Stent thrombosis is the primary cause of ST-segment elevation myocardial infarction following coronary stent implantation: a five year follow-up of the SORT OUT II study. PLoS One (2014) 0.79

Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis. Clin Res Cardiol (2013) 0.79

Correlation of angiographic late loss with neointimal coverage of drug-eluting stent struts on follow-up optical coherence tomography. Int J Cardiovasc Imaging (2011) 0.79

Quality of life (QOL) evaluation after acute coronary syndrome with simultaneous clopidogrel treatment. Arch Med Sci (2013) 0.79

Neoatherosclerosis: Coronary stents seal atherosclerotic lesions but result in making a new problem of atherosclerosis. World J Cardiol (2015) 0.79

Optimization of Drug Delivery by Drug-Eluting Stents. PLoS One (2015) 0.78

Outcome of percutaneous coronary intervention with drug-eluting stents in unprotected left main versus non-left main native coronary artery disease: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol (2013) 0.78

Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy. ISRN Cardiol (2013) 0.78

Prevention of Collagen-Induced Platelet Binding and Activation by Thermosensitive Nanoparticles. AAPS J (2015) 0.78

Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. Pharmacol Res (2014) 0.78

Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents. Heart Vessels (2011) 0.78

Neointimal coverage and vasodilator response to titanium-nitride-oxide-coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome: insights from the BASE-ACS trial. Int J Cardiovasc Imaging (2013) 0.78

Very Late Stent Thrombosis of Sirolimus-eluting Stent 59 Months After Implantation: A First Report from The Middle-East and Review of Literature. Heart Views (2011) 0.78

Role of Intravascular Ultrasound in Patients with Acute Myocardial Infarction. Korean Circ J (2015) 0.78

Nanotechnology in interventional cardiology. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.78

STENTING STRATEGY AND FOLLOW-UP RESULTS OF MULTI-CENTER REGISTRY IN FUKUSHIMA CITY FOR LEFT MAIN CORONARY ARTERY DISEASE: BARE METAL STENT VERSUS DRUG-ELUTING STENT. Fukushima J Med Sci (2015) 0.78

Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching. Yonsei Med J (2017) 0.78

Favorable Outcomes after Implantation of Biodegradable Polymer Coated Sirolimus-Eluting Stents in Diabetic Population: Results from INDOLIMUS-G Diabetic Registry. Int J Vasc Med (2015) 0.78

Articles by these authors

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J (2011) 13.10

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08

Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70

A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2012) 10.38

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J (2014) 9.73

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54

Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med (2012) 8.39

Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet (2005) 7.89

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ (2002) 7.26

Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (2011) 6.89

A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J (2003) 6.88

Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet (2009) 6.82

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51

2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J (2013) 6.17

Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med (2007) 6.17

Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet (2004) 5.94

Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ (2010) 5.68

Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49

Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med (2009) 5.26

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J (2013) 5.23

The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention (2005) 5.16

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J (2015) 5.15

Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol (2007) 5.02

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 4.94

Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med (2012) 4.87

High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation (2005) 4.68

Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med (2015) 4.68

Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med (2013) 4.62

Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med (2014) 4.37

Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet (2013) 4.34

Soluble CD40 ligand in acute coronary syndromes. N Engl J Med (2003) 4.06

Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol (2005) 4.05

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94

Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol (2004) 3.87

Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol (2007) 3.82

Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med (2012) 3.63

Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med (2005) 3.60

Quality of reporting of randomized trials as a measure of methodologic quality. JAMA (2002) 3.60

All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ (2011) 3.51

Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation (2006) 3.50

Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47

Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial. JAMA Intern Med (2013) 3.46

Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet (2013) 3.41

Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation (2007) 3.40

Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37

Lessons from the withdrawal of rofecoxib. BMJ (2004) 3.33

Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J (2011) 3.29

A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. J Am Coll Cardiol (2007) 3.28

Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19

Prognostic value of multislice computed tomography coronary angiography in patients with known or suspected coronary artery disease. J Am Coll Cardiol (2006) 3.16

Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research. Stat Med (2002) 3.16

Concern Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J (2009) 3.14

A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet (2008) 3.12

Meta-analysis: accuracy of rapid tests for malaria in travelers returning from endemic areas. Ann Intern Med (2005) 3.08

Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol (2006) 3.07

Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J (2009) 3.06

Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation (2003) 3.01

Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation (2003) 2.97

Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ (2007) 2.93

A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med (2007) 2.91

Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol (2005) 2.90

Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ (2010) 2.88

Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation (2013) 2.88

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J (2006) 2.87

Stent thrombosis. J Am Coll Cardiol (2010) 2.86

Left ventricular resynchronization is mandatory for response to cardiac resynchronization therapy: analysis in patients with echocardiographic evidence of left ventricular dyssynchrony at baseline. Circulation (2007) 2.85

Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol (2011) 2.85